Price
CHART BY
Frequently asked questions
What is Dianthus Therap's market capitalization?
The market capitalization of Dianthus Therap is $5.92B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Dianthus Therap?
Dianthus Therap's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$4.152. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Dianthus Therap's stock?
Currently, 16 analysts cover Dianthus Therap's stock, with a consensus target price of $139.36. Analyst ratings provide insights into the stock's expected performance.
What is Dianthus Therap's revenue over the trailing twelve months?
Over the trailing twelve months, Dianthus Therap reported a revenue of $1.90M.
What is the EBITDA for Dianthus Therap?
Dianthus Therap's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$217.47M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Dianthus Therap?
Dianthus Therap has a free cash flow of -$155.71M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Dianthus Therap have, and what sector and industry does it belong to?
Dianthus Therap employs approximately 92 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Dianthus Therap's shares?
The free float of Dianthus Therap is 50.51M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $5.92B
- EPS (TTM)
- -$4.152
- Free Float
- 50.51M
- Revenue (TTM)
- $1.90M
- EBITDA (TTM)
- -$217.47M
- Free Cashflow (TTM)
- -$155.71M
Pricing
- 1D span
- $105.44$107.27
- 52W span
- $23.39$117.86
Analyst Ratings
The price target is $139.36 and the stock is covered by 16 analysts.
Buy
16
Hold
0
Sell
0
Information
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
- Employees
- 92
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- DNTH
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet